Document is current
Any future updates will be listed below
-
Authors
Wang, Hao
Cao, Zhixin
Campbell, Bruce C. V.
Katsanos, Aristeidis H.
Yin, Jinfeng
Fisher, Marc
Wang, Yongjun
Xiong, Yunyun https://orcid.org/0000-0003-1353-2295
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct05141305 at ClinicalTrials.govDocuments that mention this clinical trial
Tenecteplase thrombolysis for stroke up to 24 hours after onset with perfusion imaging selection: the umbrella phase IIa CHABLIS-T randomised clinical trial
https://doi.org/10.1136/svn-2023-002820
Rationale and design of Tenecteplase Reperfusion Therapy in Acute Ischaemic Cerebrovascular Events III (TRACE III): a randomised, phase III, open-label, controlled trial
https://doi.org/10.1136/svn-2023-002310
Tenecteplase versus alteplase for acute ischaemic stroke: a meta-analysis of phase III randomised trials
https://doi.org/10.1136/svn-2023-002396
Effects of Fibrinogen on Tenecteplase Treatment in Acute Ischaemic Stroke After 4.5 Hours of Symptom Onset: A Post Hoc Analysis of the TRACE-III Trial
https://doi.org/10.1007/s40120-026-00958-4
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (82171272)
Beijing Natural Science Foundation (JQ24058)
Beijing Municipal Science & Technology Committee (Z211100003521019)
China Shijiazhuang Pharmaceutical Company Recomgen Pharmaceutical
- License Information
-
More Information
Article History
Received: 7 April 2026
Accepted: 6 May 2026
First Online: 20 May 2026
Declarations
:
: Marc Fisher serves as a consultant for Simcere USA and Lumosa; and a member of DSMB for Moleac. Hao Wang, Zhixin Cao, Bruce C.V. Campbell, Aristeindis H. Katsanos, Jinfeng Yin, Yongjun Wang, and Yunyun Xiong have nothing to disclose.
: The trial was approved by the ethics committee at Beijing Tiantan Hospital and all participating centres. Written informed consent was provided by all the patients or their representatives before enrolment. TRACE-III is registered with ClinicalTrials.gov, NCT05141305. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and the principles of the Declaration of Helsinki. The TRACE-Ⅲ study obtained ethics approval from the Institutional Review Board of Beijing Tiantan Hospital, Capital Medical University with number KY2021-129-03.
